Norman C Selby

Bio

Norman C. Selby is a Senior Advisor of Perseus. Before joining Perseus in 2005, Mr. Selby was President and CEO of TransForm Pharmaceuticals, a specialty pharmaceutical company focused on innovation in the form and formulation of drug compounds that was acquired by Johnson & Johnson in April 2005. He was also an Executive Vice President at Citigroup/Citicorp from 1997-2008. Mr. Selby spent the bulk of his career at McKinsey & Company where he was Director (Senior Partner) in the firm’s New York office. He held several leadership roles at McKinsey, including head of the firm’s Global Pharmaceuticals and Medical Products Practice. From 1987-1989, Mr. Selby took a leave of absence from McKinsey to serve as Chief Operating Officer of the New York Blood Center, the largest community blood organization in the country, where he led its financial and operational turnaround. Mr. Selby is a member of the Board of Directors of the following Perseus portfolio companies: Ascenta Therapeutics, Inc., NanoBio Corporation, and Physicians Interactive Holdings, LLC. He is also on the Supervisory Board of Merz GmbH, a private specialty pharmaceutical company based in Germany. Mr Selby was on the Board of Millennium Pharmaceuticals (MLNM) from 2000-2008 and he was Chairman of Windhover Information, the leading B2B publishing and information company in the pharmaceutical, biotechnology, and medical device industries, from 2004 until it was sold to Reed Elsevier in 2008. Mr. Selby serves on the Board of Trustees of the Central Park Conservancy, the Memorial Sloan-Kettering Cancer Center, and the Ralph Lauren Center for Cancer Care and Prevention, all based in New York City. He is also a member of the advisory board of the Harvard Business School's Healthcare Initiative and a Board member of the National Parks Conservation Association in Washington D.C. Mr. Selby holds a B.A. in Architecture from Yale College and an M.B.A. with Distinction from the Harvard Graduate School of Business Administration.